Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00563563
Other study ID # NB-401
Secondary ID
Status Completed
Phase Phase 2
First received November 21, 2007
Last updated October 31, 2012
Start date October 2007
Est. completion date September 2008

Study information

Verified date October 2012
Source Orexigen Therapeutics, Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Key Inclusion Criteria:

1. Female and male subjects must be 18 to 65 years of age;

2. Have body mass index (BMI) greater than or equal to 27 and less than or equal to 45kg/m2;

3. Have smoked an average of at least 10 cigarettes/day in the preceding year, with < 3 month total abstinence period;

4. Self-reported level of motivation to stop smoking = 7, on a scale of 1-to-10;

5. At least moderately concerned about gaining weight after quitting smoking

6. Women of child-bearing potential, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug;

7. Able to comply with all required study procedures and schedule;

8. Able to speak and read English;

9. Willing and able to give written informed consent.

Key Exclusion Criteria:

1. Obesity of known endocrine origin

2. Serious medical condition

3. History of drug or alcohol abuse or dependence

4. Use of excluded concomitant medications

5. History of surgical or device (e.g. gastric banding) intervention for obesity;

6. History or predisposition to seizures

7. Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug;

8. Planned surgical procedure that can impact the conduct of the study;

9. Use of investigational drug, device or procedure within 30 days prior to Screening;

10. Participation in any previous clinical trial conducted by Orexigen Therapeutics;

11. Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
NB32
All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
Behavioral:
Ancillary therapy
During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.

Locations

Country Name City State
United States Pharmacology Research Institute Encino California
United States Pharmacology Research Institute Los Alamitos California
United States Pharmacology Research Institute Newport Beach California

Sponsors (1)

Lead Sponsor Collaborator
Orexigen Therapeutics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess rates of smoking cessation defined by continuous abstinence. 12 weeks No
Secondary To assess the percent change from baseline in total body weight during the entire study Baseline to endpoint No
Secondary To assess the rates of smoking cessation as measured by expired CO levels <10 ppm 12 and 24 weeks No
Secondary To assess the change from baseline in tobacco use from baseline as measured by a tobacco use diary Baseline to endpoint No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2